Ibrutnib vs Retuximab - A Review

In terms of safety, the overall frequency of grade three or higher adverse events was similar between the two treatment arms. cytopenias and infection were more frequently observed in the f c r cohort. Overall survival was still superior with longer follow up, but the difference was less pronounced than previously reported. A sub group analysis for overall survival revealed that only patients with unmutated andmuno globula and heavy chan gen s s benefited from the i r combination.